Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib

Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related deaths worldwide [1]. Epidermal growth factor receptor (EGFR) gene mutations as driver oncogenes were first identified in NSCLC in 2004 and common mutations are associated with benefits from tyrosine kinase inhibitors (TKIs) [2–6]. Therefore, EGFR mutation detection is a standard method in the management of NSCLC and it is crucial in the management of cases with common or unexpected genotyping results. Approximately 50% of Asian NSCLC patients have EGFR mutations [7].